Community-Based Remote Cardiac Rehabilitation Program for Pediatric Patients With Complex Congenital Heart Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-18
SponsorSeoul National University Hospital

About this trial

This study is to develop a 12-week community-based remote cardiac rehabilitation program for pediatric patients with complex congenital heart disease and to assess its validity and safety.

For these children, a multidisciplinary approach including pediatric rehabilitation medicine, pediatric thoracic surgery, pediatrics, pediatric psychiatry, sports science, and nutrition is essential, but such comprehensive services are rarely available in Korea. As a result, pediatric cardiac rehabilitation at the community level is nearly nonexistent. Recent long-term retrospective cohort studies suggest that maintaining regular physical activity and aerobic capacity from early childhood significantly reduces future cardiovascular complications, emphasizing the importance of early pediatric cardiac rehabilitation. However, participation in existing programs is low due to limited accessibility.

The investigators hypothesize that a community-based remote cardiac rehabilitation program for these patients is both valid and safe. Participants will be children aged 8-18 years diagnosed with complex congenital heart disease , at least 3 months post-surgery, and stable cardiovascular status.

Interventions include supervised and self-directed cardiac rehabilitation exercises. Monitoring (heart rate, SpO2, ECG) will be performed in real-time, with non-real-time data collection of physical activity using smartwatches. The intervention lasts 12 weeks with a 12-week follow-up.

Validity measures include baseline evaluation, adherence, dropout rate, participant and parent satisfaction, and changes in cardiopulmonary exercise capacity, physical activity, body composition, fitness (6-minute walk, strength, flexibility, respiratory muscle strength), and questionnaires (physical activity, quality of life, exercise satisfaction, depression, psychological state).

Safety will be assessed by monitoring adverse events, vital signs, fatigue (Borg scale), and pain before and after exercise.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged between 8 and 18 years

Diagnosed with complex congenital heart disease (Complex CHD) and have undergone surgery

At least 3 months post-cardiac surgery with a stable hemodynamic status

Capable of using remote programs (e.g., mobile apps, video-conferencing platforms) at home, with technical support from a caregiver

Disqualifiers

Patients with uncontrolled arrhythmias, acute heart failure, myocarditis, pericarditis, or other ongoing cardiovascular conditions.

Patients who are unable to exercise independently due to neurological or musculoskeletal disorders.

Patients who cannot understand or carry out remote rehabilitation program instructions due to cognitive impairment.

Patients showing clinically significant levels of depression or anxiety on the CDI-2 or RCMAS.

Trial design

Design model

Single group

Treatments tested in this trial

  • Community-based supervised remote cardiac rehabilitation

    Other intervention

    Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training. Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE).

  • Home-based cardiac rehabilitation program

    Other intervention

    Beyond the single supervised session, participants undertake four weekly home-based sessions. * Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance. * Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance. * High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down).

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Community-based remote cardiac rehabilitation groupExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Drop-out rate

Time frame
baseline, 12 weeks after, 24 weeks after follow-up
2

Attendance rate

Time frame
baseline, 12 weeks after, 24 weeks after follow-up

Secondary outcomes

1

oxygen consumption, VO2

Oxygen consumption (VO2) refers to the rate at which the body takes in and uses oxygen.

Time frame
baseline, 12 weeks after, 24 weeks after follow-up
2

maximal oxygen consumption, VO2 max

Maximal oxygen consumption (VO2 max) represents the highest rate at which an individual can take in, transport, and utilize oxygen during maximal or exhaustive exercise.

Time frame
baseline, 12 weeks after, 24 weeks after follow-up
3

Respiratory exchange rate, RER

Respiratory Exchange Ratio (RER) is the ratio of the volume of carbon dioxide produced (VCO2) to the volume of oxygen consumed (VO2) in the body. RER = VCO2 / VO2

Time frame
baseline, 12 weeks after, 24 weeks after follow-up
4

minute ventilation (VE)

minute ventilation (VE) refers to the total volume of air inhaled or exhaled by an individual per minute. VE = Tidal Volume (VT) x Respiratory Rate (RR)

Time frame
baseline, 12 weeks after, 24 weeks after follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Seoul National University Hospital

Lead sponsor

University of Seoul

Collaborator

This trial is not recruiting at the moment. You can still explore other options: